Skip to main content

Kevin Erreger

Sr Research Specialist, Pharmacology

2004 Emory University Ph.D. (Neuroscience)
1998 State University of New York at Buffalo B.S. (Biophysics)

Research Interests:
My background is in biophysics and physiology and my current research interests focus on translational research and drug development. I coordinate multiple collaborative projects focused on Protease Activated Receptor 4 (PAR4). We are developing novel PAR4 antagonists for clinical use and also as tools for mouse models of disease. We view PAR4 as a relevant target to investigate in disease processes with inflammatory pathology. Currently, we are investigating the role of PAR4 in Azlheimer’s, kidney disease, and COVID-19.

Yim YY, McDonald WH, Betke KM, Kaya A, Hyde K, Erreger K, Gilsbach R, Hein L, Hamm HE.
Specificities of Gβγ subunits for the SNARE complex before and after stimulation of α2a-adrenergic receptors. Sci Signal. 2021 Dec 21;14(714):eabc4970.

Herborg F, Jensen KL, Tolstoy S, Arends NV, Posselt LP, Shekar A, Aguilar JI, Lund VK, Erreger K, Rickhag M, Lycas MD, et al., Identifying dominant-negative actions of a dopamine transporter variant in patients with parkinsonism and neuropsychiatric disease. JCI Insight, 2021. 6(18).

Pulley JM, Rhoads JP, Jerome RN, Challa AP, Erreger K, Joly MM, Lavieri RR, Perry KE, Zaleski NM, Shirey-Rice JK, and Aronoff DM, Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. Annu Rev Pharmacol Toxicol, 2020. 60: p. 333-352.

Campbell NG, Shekar A, Aguilar JI, Peng D, Navratna V, Yang D, Morley AN, Duran AM, Galli G, O’Grady B, Ramachandran R, Erreger K, et al., Galli A, Structural, functional, and behavioral insights of dopamine dysfunction revealed by a deletion in SLC6A3. Proc Natl Acad Sci U S A, 2019. 116(9): p. 3853-3862.
Reddy IA, Smith NK, Erreger K, Ghose D, Saunders C, Foster DJ, Turner B, Poe A, Albaugh VL, McGuinness O, Hackett TA, et al., Bile diversion, a bariatric surgery, and bile acid signaling reduce central cocaine reward. PLoS Biol, 2018. 16(7): p. e2006682.

Reddy IA, Pino JA, Weikop P, Osses N, Sorensen G, Bering T, Valle C, Bluett RJ, Erreger K, Wortwein G, Reyes JG, et al., Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Transl Psychiatry, 2016. 6: p. e809.
Hamilton PJ, Shekar A, Belovich AN, Christianson NB, Campbell NG, Sutcliffe JS, Galli A, Matthies HJ, and Erreger K, Zn(2+) reverses functional deficits in a de novo dopamine transporter variant associated with autism spectrum disorder. Mol Autism, 2015. 6: p. 8.

Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJ, Niswender K, and Galli A, mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. J Neurosci, 2015. 35(23): p. 8843-54.
Cartier E, Hamilton PJ, Belovich AN, Shekar A, Campbell NG, Saunders C, Andreassen TF, Gether U, Veenstra-Vanderweele J, Sutcliffe JS, Ulery-Reynolds PG, et al., Erreger K, Galli A, Rare autism-associated variants implicate syntaxin 1 (STX1 R26Q) phosphorylation and the dopamine transporter (hDAT R51W) in dopamine neurotransmission and behaviors. EBioMedicine, 2015. 2(2): p. 135-146.

Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, Ahmad J, Thiele H, Kubisch C, Rider NL, Morton DH, et al., Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain, 2014. 137(Pt 4): p. 1107-19.
Hansen FH, Skjorringe T, Yasmeen S, Arends NV, Sahai MA, Erreger K, Andreassen TF, Holy M, Hamilton PJ, Neergheen V, Karlsborg M, et al., Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest, 2014. 124(7): p. 3107-20.

Hamilton PJ, Belovich AN, Khelashvili G, Saunders C, Erreger K, Javitch JA, Sitte HH, Weinstein H, Matthies HJG, and Galli A, PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nat Chem Biol, 2014. 10(7): p. 582-589.

Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, Blakely RD, Sutcliffe J, et al., Erreger K, Galli A, SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl Psychiatry, 2014. 4: p. e464.

Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN, Consortium NAAS, Sahai MA, Cook EH, Gether U, et al., De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry, 2013. 18(12): p. 1315-23.

Hamilton PJ, Campbell NG, Sharma S, Erreger K, Hansen FH, Saunders C, Belovich AN, Sahai MA, Cook EH, Gether U, McHaourab HS, et al., Drosophila melanogaster: a novel animal model for the behavioral characterization of autism-associated mutations in the dopamine transporter gene. Mol Psychiatry, 2013. 18(12): p. 1235.

Graham DL, Erreger K, Galli A, and Stanwood GD, GLP-1 analog attenuates cocaine reward. Mol Psychiatry, 2013. 18(9): p. 961-2.

Dixit M, Kim S, Matthews GF, Erreger K, Galli A, Cobb CE, Hustedt EJ, and Beth AH, Structural arrangement of the intracellular Ca2+ binding domains of the cardiac Na+/Ca2+ exchanger (NCX1.1): effects of Ca2+ binding. J Biol Chem, 2013. 288(6): p. 4194-207.

Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD, and Galli A, Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav, 2012. 106(4): p. 574-8.

Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, et al., Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci, 2010. 30(17): p. 6048-57.

Erreger K and Traynelis SF, Zinc inhibition of rat NR1/NR2A N-methyl-D-aspartate receptors. J Physiol, 2008. 586(3): p. 763-78.

Erreger K, Grewer C, Javitch JA, and Galli A, Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function. J Neurosci, 2008. 28(4): p. 976-89.

Chen PE, Geballe MT, Katz E, Erreger K, Livesey MR, O’Toole KK, Le P, Lee CJ, Snyder JP, Traynelis SF, and Wyllie DJ, Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol, 2008. 586(1): p. 227-45.

Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, Zhang M, Sen N, Colbran RJ, Gnegy ME, Gether U, et al., Erreger K, Galli A, Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol, 2008. 74(4): p. 1101-8.

Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, Micale N, Jorgensen L, et al., Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol, 2007. 72(4): p. 907-20.

Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, et al., Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol, 2007. 581(Pt 1): p. 107-28.
Yuan H, Erreger K, Dravid SM, and Traynelis SF, Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem, 2005. 280(33): p. 29708-16.

Erreger K and Traynelis SF, Allosteric interaction between zinc and glutamate binding domains on NR2A causes desensitization of NMDA receptors. J Physiol, 2005. 569(Pt 2): p. 381-93.

Erreger K, Geballe MT, Dravid SM, Snyder JP, Wyllie DJ, and Traynelis SF, Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci, 2005. 25(34): p. 7858-66.

Erreger K, Dravid SM, Banke TG, Wyllie DJ, and Traynelis SF, Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol, 2005. 563(Pt 2): p. 345-58.

Erreger K, Chen PE, Wyllie DJ, and Traynelis SF, Glutamate receptor gating. Crit Rev Neurobiol, 2004. 16(3): p. 187-224.
Zheng F, Erreger K, Low CM, Banke T, Lee CJ, Conn PJ, and Traynelis SF, Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A. Nat Neurosci, 2001. 4(9): p. 894-901.

Mott DD, Erreger K, Banke TG, and Traynelis SF, Open probability of homomeric murine 5-HT3A serotonin receptors depends on subunit occupancy. J Physiol, 2001. 535(Pt 2): p. 427-43.